Kintegral Advisory LLC Reduces Holdings in Stryker Corporation (NYSE:SYK)

Kintegral Advisory LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 33.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,055 shares of the medical technology company's stock after selling 1,010 shares during the quarter. Kintegral Advisory LLC's holdings in Stryker were worth $767,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Stryker by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock valued at $11,773,213,000 after purchasing an additional 252,188 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Stryker by 0.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company's stock valued at $4,000,056,000 after purchasing an additional 54,693 shares during the period. FMR LLC increased its position in shares of Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after buying an additional 727,850 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company's stock valued at $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Stryker during the 4th quarter worth approximately $1,710,744,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Needham & Company LLC reissued a "buy" rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Citigroup restated a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Evercore ISI cut their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Truist Financial raised their target price on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research report on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Stryker Stock Up 0.0%

Shares of SYK stock traded up $0.19 during trading on Friday, reaching $392.00. The company's stock had a trading volume of 536,295 shares, compared to its average volume of 1,346,875. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19. The stock's 50-day moving average price is $382.92 and its 200 day moving average price is $376.13. The company has a market capitalization of $149.62 billion, a price-to-earnings ratio of 52.97, a P/E/G ratio of 2.98 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.50 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.